Alpha2-adrenoceptors in adrenomedullary chromaffin cells: functional role and pathophysiological implications
Loading...
Official URL
Full text at PDC
Publication date
2017
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Citation
Artalejo, Antonio R., y Luis Alcides Olivos-Oré. «Alpha2-Adrenoceptors in Adrenomedullary Chromaffin Cells: Functional Role and Pathophysiological Implications». Pflügers Archiv - European Journal of Physiology, vol. 470, n.o 1, enero de 2018, pp. 61-66. https://doi.org/10.1007/s00424-017-2059-y.
Abstract
Chromaffin cells from the adrenal medulla participate in stress responses by releasing catecholamines into the bloodstream. Main control of adrenal catecholamine secretion is exerted both neurally (by the splanchnic nerve fibers) and humorally (by corticosteroids, circulating noradrenaline, etc.). It should be noted, however, that secretory products themselves (catecholamines, ATP, opioids, ascorbic acid, chromogranins) could also influence the secretory response in an autocrine/paracrine manner. This form of control is activity-dependent and can be either inhibitory or excitatory.Among the inhibitory influences, it stands out the one mediated by α2-adrenergic autoreceptors activated by released catecholamines. α2-adrenoceptors areGprotein-coupledreceptors capable to inhibit exocytotic secretion through a direct interaction ofGβγ subunits with voltage-gated Ca2+ channels. Interestingly, upon intense and/or prolonged stimulation, α2-adrenergic receptors become desensitized by the intervention of G protein-coupled receptor kinase 2 (GRK2). In several experimental models of heart failure, there hasbeenreportedthe up-regulationofGRK2 and the loss of functioning of inhibitory α2-adrenoceptors resulting in enhanced release of adrenomedullary catecholamines. Given the importance of circulating catecholamines in the pathophysiology of heart failure, the recovery of α2-adrenergic modulation of the secretory response from chromaffin cells appears as a novel strategy for a better control of the patients with this cardiac disease.